Navigation Links
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Date:12/4/2008

mong others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarter Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2008.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015   Surefire Medical, Inc. today ... the Surefire Infusion System with an end hole ... liver cancer, using the Surefire resulted in statistically ... and with significantly decreased uptake in normal liver ... Society of Interventional Radiology (SIR) meeting ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Global POC Diagnostics Market 2015-2019" report to ... the Global POC Diagnostics market to grow at a ... POC diagnostics are IVD devices and tools ... laboratory setting. The use of these devices helps in ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... Council today recognized world-class manufacturing companies and ... Manufacturing Leadership Awards. Logo - ... world of intensifying global competition and accelerating, ... have distinguished themselves by embracing breakthrough innovation ...
Breaking Medicine Technology:Clinical Trial Comparing the Surefire Infusion Device to an End Hole Catheter Finds Surefire Increases Tumor Uptake and Decreases Non-Target Embolization In Every Patient, Multiple Liver Cancer Types 2Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 22015 Manufacturing Leadership Award Winners Announced 22015 Manufacturing Leadership Award Winners Announced 32015 Manufacturing Leadership Award Winners Announced 42015 Manufacturing Leadership Award Winners Announced 52015 Manufacturing Leadership Award Winners Announced 6
... , PLYMOUTH, Mich. and BATON ROUGE, ... a privately held biopharmaceutical company working to discover, develop ... announced that TransGenRx, a global leader in transgenic technology, ... company,s research efforts targeting HDL therapies for the treatment ...
... , June 21, 2010 PolyTouch Medical Ltd., ... that it has received broad FDA 510(k) clearance,to commercialize PatchAssist(TM). ... rapid delivery and placement of,soft tissue prosthetics for a variety ... , , ...
Cached Medicine Technology:TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics 2TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics 3PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist(TM) - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects 2PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist(TM) - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects 3
(Date:3/3/2015)... 03, 2015 eMedEvents, a searchable ... medical education (CME) credit information, has officially been ... was initially launched in the United States (December ... kind in the field of healthcare conference technology ... this Denver, Colorado-based start-up company was successful as ...
(Date:3/3/2015)... Auckland, New Zealand and Rockville, Maryland (PRWEB) March ... has selected Cornerstone Communications, LTD as its North ... record. Cornerstone was awarded the Manuka Lab contract ... beauty, and consumer verticals. , Headquartered in Auckland, ... private company focused on providing clients effective, certified ...
(Date:3/3/2015)... State after state prove the ... probation programs aimed to rehabilitate nonviolent drug offenders. ... cost of incarcerating violators of drug laws, as ... addiction treatment. Governor Bruce Rauner ( R)has proposed ... drug and alcohol statewide Department of Alcoholism and ...
(Date:3/3/2015)... York, NY (PRWEB) March 03, 2015 Ticket ... tickets for her 2015 tour. This well-known ticket ... added savings. , Arguably the biggest name in the music ... when Madonna performs on the “Rebel Heart Tour.” Madonna, fresh ... month will kick off her latest tour on August 29th ...
(Date:3/3/2015)... 2015 Raritan Bay Medical Center is ... an interactive photo contest held at the Woodbridge Center ... To raise awareness for health and wellness in the ... their best health and wellness tips. , Photos of ... Center’s website and Facebook page where Facebook users voted ...
Breaking Medicine News(10 mins):Health News:eMedEvents Launches Online Medical Conference, Speaker and CME Platform in India 2Health News:Manuka Lab North America, Inc. Awards Cornerstone Communications, LTD North American Agency Contract 2Health News:Gov. of Illinois, Bruce Rauner, Suggests Cutting 25 Million for Drug Rehabilitation, Harbor Village Comments 2Health News:Cheap Madonna Tickets: Madonna Presale Tickets in Miami, New York, Brooklyn, Chicago, San Jose, Toronto, Edmonton & Vancouver Now Available at TicketDown.com 2Health News:Cheap Madonna Tickets: Madonna Presale Tickets in Miami, New York, Brooklyn, Chicago, San Jose, Toronto, Edmonton & Vancouver Now Available at TicketDown.com 3Health News:Raritan Bay Medical Center Announces Winners of “Picture of Health” Photo Contest 2
... PRINCETON, N.J., Feb. 19 Medarex, Inc. (Nasdaq: ... its 2008 fourth quarter and year-end results on ... the financial markets close. Following the release, Medarex,s ... webcast at 4:30 p.m. Eastern Time. To access ...
... CVD ) today announced that it has elected ... Dr. Sheares is former chief executive officer and member of ... company that marketed a portfolio of branded cardiovascular medicines. Prior ... Health division of Merck and Co., Inc., where he led ...
... to know the least, survey finds, , , THURSDAY, Feb. 19 (HealthDay ... of a stroke and what to do if they suspect one ... research. , Older people and those who,ve already had a stroke ... the symptoms of a stroke and know to immediately call 911. ...
... PLC, a subsidiary of MGT Capital Investments, Inc. ... development of Computer-Aided Detection (CAD) and image analysis ... of disease, today announces the following restructuring of ... Rowley, currently Chief Financial Officer, becomes Chief Executive ...
... Feb. 19 A groundbreaking new survey sponsored by ... 82% of young adults aged 18-30 plan to get ... 40% of first marriages end in divorce. Why?"There is ... reality of getting or being married," says Mary Myrick, ...
... 2009 A new study released today found blacks ... replacement, an important intervention for reducing pain and improving ... study also found total knee replacements are increasing substantially ... the research underscores the need for healthcare providers and ...
Cached Medicine News:Health News:Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009 2Health News:Covance Elects Bradley T. Sheares to Company's Board of Directors 2Health News:Know the Warning Signs of Stroke? Most Don't. 2Health News:Medicsight PLC Restructures Management Team 2Health News:Medicsight PLC Restructures Management Team 3Health News:Young People Want 'Happily Ever After,' but Lack Skills to Make Marriage Work 2Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 2Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: